Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The incidence of acute hepatitis C virus (HCV) in HIV-positive patients is rising. Recent studies summarized by the European AIDS Treatment Network (NEAT)(1) show that pegylated interferon alpha (PEG-IFNα) and ribavirin can lead to a sustained virological response (SVR) in approximately 60-80% of patients. Controversy remains on when to start treatment and whether 24 or 48 weeks of treatment lead to better outcomes. OBJECTIVES: To assess the effectiveness of a treatment strategy for acute HCV infection in HIV-positive patients, in which patients with undetectable HCV RNA at 4 weeks (rapid virological response, RVR) receive 24 weeks, while those without receive 48 weeks of PEG-IFNα and ribavirin, as per the NEAT guidelines. STUDY DESIGN: A retrospective cohort study of HIV-positive patients diagnosed with acute HCV infection between December 2006 and May 2010. Those who received acute treatment with PEG-IFNα and ribavirin had HCV RNA levels monitored and outcomes evaluated. For patients who did not receive acute treatment, the reason for deferral and most recent available HCV RNA were recorded. RESULTS: Twenty-two patients received acute treatment with PEG-IFNα and ribavirin. Twelve patients achieved RVR and had 24 weeks treatment, 10 patients had no RVR and had 48 weeks treatment. Two patients discontinued treatment (due to adverse effects [AEs] and failure to suppress HCV RNA sufficiently at 12 weeks). All 20 patients who completed treatment had SVR. CONCLUSION: Our high SVR rate of 91% supports the new NEAT treatment duration recommendations.

Original publication

DOI

10.1016/j.jcv.2011.08.020

Type

Journal article

Journal

J Clin Virol

Publication Date

12/2011

Volume

52

Pages

367 - 369

Keywords

Adult, Antiviral Agents, Cohort Studies, Female, HIV Infections, Hepatitis C, Humans, Interferon-alpha, Male, Middle Aged, Practice Guidelines as Topic, RNA, Viral, Retrospective Studies, Ribavirin, Time Factors, Treatment Outcome